DISSECTIONING RISK FACTORS FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML) AFTER AUTOTRANSPLANTS FOR PLASMA CELL MYELOMA AND LYMPHOMAS

被引：0
|
作者：
Hashmi, S. [1 ]
Dean, R. M. [2 ]
Shaw, B. [3 ]
Brazauskas, R. [3 ]
Millard, H. [3 ]
Battiwalla, M. [4 ]
Savani, B. [5 ]
Flowers, M. E. [6 ]
Cooke, K. R. [7 ]
Hamilton, B. K. [2 ]
Kalaycio, M. [8 ]
Radivoyevitch, T. [9 ]
Litzow, M. R. [10 ,11 ]
Gale, R. P. [12 ]
机构：
[1] Mayo Clin, Bone Marrow Transplant Program, Rochester, MN USA
[2] Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH USA
[3] MCW, CIBMTR, Milwaukee, WI USA
[4] NHLBI, Hematol Branch, Bethesda, MD 20892 USA
[5] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[6] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[7] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Pediat Blood & Marrow Transplantat Program, Baltimore, MD USA
[8] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[9] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
[10] Mayo Clin, Div Hematol, Rochester, MN USA
[11] Mayo Clin, Transplant Ctr, Rochester, MN USA
[12] Imperial Coll London, Dept Med, Sect Hematol, London, England
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30174-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
61
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [31] Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Demakos, Erin P.
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2013, 122 (21)
  • [32] Dose reduced conditioning and allogeneic stem cell transplantation in 34 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Bornhauser, M
    Kroschinsky, F
    Ulrike, S
    Markus, S
    Eberhard, S
    Ralph, N
    Thiede, C
    Ulrich, S
    Gerhard, E
    BLOOD, 2000, 96 (11) : 780A - 780A
  • [33] Risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after adjuvant chemotherapy (CT) for early breast cancer (BC) in the community setting.
    Denduluri, Neelima
    Espirito, Janet L.
    Turnwald, Brian
    Wang, Yunfei
    Asmar, Lina
    Hoverman, J. Russell
    Neubauer, Marcus A.
    Bosserman, Linda D.
    Busby, Leslie T.
    Brooks, Barry Don
    Cartwright, Thomas H.
    Sitarik, Mark A.
    Schnadig, Ian D.
    Winter, William E.
    Garey, Jody S.
    Bergstrom, Kimberly A.
    Beveridge, Roy A.
    Patt, Debra A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [34] Multidimensional Deep T-cell Phenotyping Defines Immune Response in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Rozenova, Krasimira
    El Daker, Sary
    Baik, Jeeyeon
    Zhu, Menglei
    Dogan, Ahmet
    Roshal, Mikhail
    Galera, Pallavi
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1229 - S1230
  • [35] Dose reduced conditioning and allogeneic stem cell transplantation in 36 patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Bornhäuser, M
    Schaich, M
    Schaekel, U
    Mahlberg, R
    Clemens, M
    Ehninger, G
    BONE MARROW TRANSPLANTATION, 2001, 27 : S85 - S85
  • [36] WHO classification af acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)
    Haferlach, T
    Schoch, C
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (09) : 447 - 450
  • [37] IMMUNOHISTOCHEMICAL AND CYTOGENETIC CORRELATION WITH TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    Chai, J.
    Nwaoduah, N.
    Shi, Y.
    Verma, A.
    Gong, J.
    Wang, Y.
    LEUKEMIA RESEARCH, 2021, 108 : S23 - S24
  • [38] Therapy-related myelodysplastic syndrome (t-MDS) following treatment of acute myeloid leukemia (AML)
    Arana-Yi, C.
    Block, A. W.
    Sait, S. N.
    Ford, L. A.
    Barcos, M.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)
    Galili, Naomi
    Trifonov, Vladimir
    Ewalt, Mark
    Mukherjee, Siddhartha
    Rabadan, Raul
    Raza, Azra
    BLOOD, 2012, 120 (21)
  • [40] Del 5q as a sole cytogenetic abnormality in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Washington, LT
    Glassman, A
    Ibrahim, S
    Lai, R
    LABORATORY INVESTIGATION, 2001, 81 (01) : 182A - 182A
12345